Rahul Banerjee

Has grant

Assistant Professor, Division of Medical Oncology

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rahul Banerjee is an Assistant Professor in the Division of Medical Oncology at the Fred Hutchinson/University of Washington Cancer Consortium. He is based in the United States and specializes in research areas such as multiple myeloma therapy, CAR-T cell therapy, and quality of life assessments in oncology. His recent articles discuss immunoglobulin prophylaxis following bispecific antibody therapy and the management of complications associated with CAR-T therapies in myeloma patients.

Recent Grants

Grant: Close

Efficacy of digital life coaching to lower benzodiazepine usage and improve quality of life in multiple myeloma patients undergoing transplantation

Open Date: 2020-07-01

Close Date: 2023-01-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Samuel Kareff

University of Miami School of Medicine

UNITED STATES

View details

Marcos de Lima

Ohio State University

UNITED STATES

View details

sandra susanibar adaniya

Assistant Professor

University of Pennsylvania

UNITED STATES

View details

Hira Mian

CANADA

View details

Ana I Velazquez

Assistant Professor

University of California, San Francisco

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rahul Banerjee

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels

Avoid burning bridges before CAR-T therapy in myeloma

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy

Step Count, Step Aside: Newer Physical Activity Metrics to Predict Survival in Oncology

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT

Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT

Double trouble: Non-relapse mortality with bispecific antibodies in lymphoma and myeloma

Novel Treatment Options for Multiple Myeloma

Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma

Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma

Professional Challenges for United States Hematology/Oncology Trainees during COVID-19

Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy

Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single‐centre retrospective study

Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships

Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma

Where the Sidewalk Ends: Parenting as a trainee during COVID-19.

Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma

Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma.

Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis.

Collaborators (5)

Samuel Kareff

Marcos de Lima

sandra susanibar adaniya

Hira Mian

Ana I Velazquez

Make your next move.